Supplementary Table S9 from FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial

Authors

Publication Details

Published
2025-09-02
DOI
https://doi.org/10.1158/1078-0432.30029008
Primary Topic
Advanced Breast Cancer Therapies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Supplementary Table S9 from FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial

Laura Torrecillas, Francisco Ayala, Federico Rojo, Begoña Bermejo et al.
Advanced Breast Cancer Therapies
article

Supplementary Table S9 from FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial

Laura Torrecillas, Francisco Ayala, Federico Rojo, Begoña Bermejo, José Bines, Roberto Torres, Agustí Barnadas, José Á. García-Sáenz, Antonio Llombart‐Cussac, Lourdes Calvo, Raúl Rincón, Jesús Herránz, Juan de la Haba-Rodríguez, Ángel Guerrero‐Zotano, José Manuel Baena-Cañada, Henry Gómez, María Rodríguez de la Borbolla, Manuel Ruíz-Borrego, Rosalía Caballero, Sandra Pérez‐Buira, Miguel Martín, Carlos H. Barrios, Partha S. Ray, Clive R. Taylor
article en

Abstract

No abstract available for this paper.
Openalex Percentile: Top 66%
Advanced Breast Cancer Therapies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.